PHARMACEUTICAL PREPARATIONS
ADARx Pharmaceuticals, Inc. Common Stock
ADRX
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
No ratio data was found for ADRX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 |
|---|---|
| Revenue | $2.22M |
| Cost of revenue | $0 |
| Gross profit | $2.22M |
| Selling, general and administrative | $7.68M |
| Research and development | $26.71M |
| Total operating expenses | $34.39M |
| Operating income | -$32.18M |
| Interest expense | $3.48M |
| Income before taxes | -$28.12M |
| Income taxes | $0 |
| Net income | -$28.12M |
| Net income attributable to common shareholders | -$28.12M |
| EBITDA | -$32.18M |
| Basic earnings per share | -$1.74 |
| Diluted earnings per share | -$1.74 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.